1-20 of 195
Sort by
News

Azacitidine, Venetoclax Effective as Treatment for Acute Myeloid Leukemia

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
December 2025
View News titled, Azacitidine, Venetoclax Effective as Treatment for Acute Myeloid Leukemia
News

Early Data Indicate Ziftomenib Plus Venetoclax/Azacitidine Effective for NPM1-Mutated AML

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
December 2025
View News titled, Early Data Indicate Ziftomenib Plus Venetoclax/Azacitidine Effective for NPM1-Mutated AML
News

Inferior Survival in Black Patients with AML Is Independent of Cytogenetic Profiles

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
December 2025
View News titled, Inferior Survival in Black Patients with AML Is Independent of Cytogenetic Profiles
News

ATRA-ATO Combination Therapy Improves Efficacy for Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia Over Standard of Care

Free
Anna Azvolinsky, PhD
Published: 2025
Abstract
December 2025
View News titled, ATRA-ATO Combination Therapy Improves Efficacy for Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia Over Standard of Care
News

FLAG-IDA Plus Venetoclax Performs Well in Children, AYA with Newly Diagnosed AML

Free
Leah Lawrence
Published: 2025
Abstract
November 2025
View News titled, FLAG-IDA Plus Venetoclax Performs Well in Children, AYA with Newly Diagnosed AML
News

Revumenib Looks to Fill a Therapeutic Void for Patients With R/R NPM1-Mutated AML

Free
Published: 2025
Abstract
October 2025
View News titled, Revumenib Looks to Fill a Therapeutic Void for Patients With R/R NPM1-Mutated AML
News

p53 IHC Testing May Be Reliable Surrogate for Early Identification of TP53-Mutated MDS, AML

Free
Leah Lawrence
Published: 2025
Abstract
October 2025
View News titled, p53 IHC Testing May Be Reliable Surrogate for Early Identification of TP53-Mutated MDS, AML
News

Intermediate Dose of Cytarabine as Effective as Higher Dose for Post-Induction in AML

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
October 2025
View News titled, Intermediate Dose of Cytarabine as Effective as Higher Dose for Post-Induction in AML
News

ASAP Trial Challenges Standard Practice of Remission Induction Before Transplant in AML

Free
Khylia Marshall
Published: 2025
Abstract
October 2025
View News titled, ASAP Trial Challenges Standard Practice of Remission Induction Before Transplant in AML
News

Menin Inhibitor Revumenib Yields Clinically Meaningful Responses in R/R NPM1-Mutated AML

Free
Leah Lawrence
Published: 2025
Abstract
August 2025
View News titled, Menin Inhibitor Revumenib Yields Clinically Meaningful Responses in R/R NPM1-Mutated AML
News

Phase II Results Point Toward a New Era in Treating Acute Myeloid Leukemia

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
July 2025
View News titled, Phase II Results Point Toward a New Era in Treating Acute Myeloid Leukemia
News

Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML

Free
Leah Lawrence
Published: 2025
Abstract
June 2025
View News titled, Magrolimab Plus Azacitidine Did Not Improve Outcomes in TP53-Mutated AML
News

Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML

Free
Anna Azvolinsky, PhD
Published: 2025
Abstract
May 2025
View News titled, Venetoclax Plus Decitabine Shows Similar Efficacy to Intensive Chemotherapy as Front- Line Therapy for Young, Fit Patients With AML
News

Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Detailed Analysis of TP53 Status Predicts Transplantation Outcomes in Patients With MDS/AML
News

Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML

Free
Leah Lawrence
Published: 2025
Abstract
April 2025
View News titled, Final CAVEAT Results Further Support Venetoclax Plus Intensive Chemotherapy in Older Patients With AML
News

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T, NCT04161885)

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T, NCT04161885)
News

Obecabtagene Autoleucel Effective Treatment for Adults with B-ALL

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
March 2025
View News titled, Obecabtagene Autoleucel Effective Treatment for Adults with B-ALL
News

CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study

Free
Katie Robinson
Published: 2025
Abstract
April 2025
View News titled, CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study
News

Predicting Response to Obe-Cel in Patients With R/R B-ALL

Free
Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Predicting Response to Obe-Cel in Patients With R/R B-ALL
News

Combination of Venetoclax, Lower Intensity CPX-351 Shows Positive Results in Early-Stage AML Study

Free
Anna Azvolinsky, PhD
Published: 2025
Abstract
February 2025
View News titled, Combination of Venetoclax, Lower Intensity CPX-351 Shows Positive Results in Early-Stage AML Study